{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T10:40:10Z","timestamp":1777977610892,"version":"3.51.4"},"reference-count":60,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T00:00:00Z","timestamp":1749081600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Acta Pharmacol Sin"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1038\/s41401-025-01535-5","type":"journal-article","created":{"date-parts":[[2025,6,5]],"date-time":"2025-06-05T05:08:49Z","timestamp":1749100129000},"page":"3009-3021","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["The conformational epitope of a gp41-specific mucosal protective IgA binds to the HIV-1 envelope and neutralizes infection"],"prefix":"10.1038","volume":"46","author":[{"given":"In\u00e8s","family":"Sahnoune","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9a","family":"Cottignies-Calamarte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annouk","family":"Dauvilliers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kingsley","family":"Essemiah","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tahar","family":"Bouceba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christophe","family":"Piesse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniela","family":"Tudor","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Morgane","family":"Bomsel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,6,5]]},"reference":[{"key":"1535_CR1","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1016\/j.tim.2019.06.002","volume":"27","author":"B Chen","year":"2019","unstructured":"Chen B. Molecular mechanism of HIV-1 entry. Trends Microbiol. 2019;27:878\u201391.","journal-title":"Trends Microbiol"},{"key":"1535_CR2","doi-asserted-by":"publisher","first-page":"e14813","DOI":"10.1371\/journal.pone.0014813","volume":"6","author":"L Ye","year":"2011","unstructured":"Ye L, Wen Z, Dong K, Wang X, Bu Z, Zhang H, et al. Induction of HIV neutralizing antibodies against the MPER of the HIV envelope protein by HA\/gp41 chimeric protein-based DNA and VLP vaccines. PLoS One. 2011;6:e14813.","journal-title":"PLoS One"},{"key":"1535_CR3","doi-asserted-by":"publisher","first-page":"1805","DOI":"10.2174\/1381612043384448","volume":"10","author":"MJ Root","year":"2004","unstructured":"Root MJ, Steger HK. HIV-1 gp41 as a target for viral entry inhibition. Curr Pharm Des. 2004;10:1805\u201325.","journal-title":"Curr Pharm Des"},{"key":"1535_CR4","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1016\/S0092-8674(00)81430-0","volume":"93","author":"DC Chan","year":"1998","unstructured":"Chan DC, Kim PS. HIV entry and its inhibition. Cell. 1998;93:681\u20134.","journal-title":"Cell"},{"key":"1535_CR5","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.2174\/1381612811319100004","volume":"19","author":"Y He","year":"2013","unstructured":"He Y. Synthesized peptide inhibitors of HIV-1 gp41-dependent membrane fusion. Curr Pharm Des. 2013;19:1800\u20139.","journal-title":"Curr Pharm Des"},{"key":"1535_CR6","doi-asserted-by":"publisher","first-page":"5801","DOI":"10.1128\/JVI.00373-15","volume":"89","author":"Y Su","year":"2015","unstructured":"Su Y, Chong H, Qiu Z, Xiong S, He Y. Mechanism of HIV-1 resistance to short-peptide fusion inhibitors targeting the Gp41 pocket. J Virol. 2015;89:5801\u201311.","journal-title":"J Virol"},{"key":"1535_CR7","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.2174\/138161210790963751","volume":"16","author":"I Steffen","year":"2010","unstructured":"Steffen I, P\u00f6hlmann S. Peptide-based inhibitors of the HIV envelope protein and other class I viral fusion proteins. Curr Pharm Des. 2010;16:1143\u201358.","journal-title":"Curr Pharm Des"},{"key":"1535_CR8","doi-asserted-by":"publisher","first-page":"3716","DOI":"10.2174\/138161210794079218","volume":"16","author":"D Eggink","year":"2010","unstructured":"Eggink D, Berkhout B, Sanders RW. Inhibition of HIV-1 by fusion inhibitors. Curr Pharm Des. 2010;16:3716\u201328.","journal-title":"Curr Pharm Des"},{"key":"1535_CR9","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1002\/cmdc.201000289","volume":"5","author":"L Cai","year":"2010","unstructured":"Cai L, Jiang S. Development of peptide and small-molecule HIV-1 fusion inhibitors that target gp41. ChemMedChem. 2010;5:1813\u201324.","journal-title":"ChemMedChem"},{"key":"1535_CR10","doi-asserted-by":"publisher","first-page":"2175","DOI":"10.1056\/NEJMoa035026","volume":"348","author":"JP Lalezari","year":"2003","unstructured":"Lalezari JP, Henry K, O\u2019Hearn M, Montaner JSG, Piliero PJ, Trottier B. et al. Enfuvirtide, an HIV-1 fusion inhibitor, for drug-resistant HIV infection in North and South America. N Engl J Med. 2003;348:2175\u201385.","journal-title":"N Engl J Med"},{"key":"1535_CR11","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1086\/378302","volume":"37","author":"JS Cervia","year":"2003","unstructured":"Cervia JS, Smith MA. Enfuvirtide (T-20): a novel human immunodeficiency virus type 1 fusion inhibitor. Clin Infect Dis.2003;37:1102\u20136.","journal-title":"Clin Infect Dis."},{"key":"1535_CR12","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1592\/phco.24.2.198.33141","volume":"24","author":"H Hardy","year":"2004","unstructured":"Hardy H, Skolnik PR. Enfuvirtide, a new fusion inhibitor for therapy of human immunodeficiency virus infection. Pharmacotherapy. 2004;24:198\u2013211.","journal-title":"Pharmacotherapy"},{"key":"1535_CR13","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1128\/JVI.79.8.4991-4999.2005","volume":"79","author":"JD Reeves","year":"2005","unstructured":"Reeves JD, Lee FH, Miamidian JL, Jabara CB, Juntilla MM, Doms RW. Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization. J Virol. 2005;79:4991\u20139.","journal-title":"J Virol"},{"key":"1535_CR14","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1093\/jac\/dkh330","volume":"54","author":"ML Greenberg","year":"2004","unstructured":"Greenberg ML, Cammack N. Resistance to enfuvirtide, the first HIV fusion inhibitor. J Antimicrob Chemother. 2004;54:333\u201340.","journal-title":"J Antimicrob Chemother"},{"key":"1535_CR15","doi-asserted-by":"crossref","unstructured":"Su S, Xu W, Jiang S. Virus entry inhibitors: past, present, and future. In: Jiang S, Lu L, editors. Virus entry inhibitors. Singapore: Springer Singapore; 2022. p. 1\u201113. (Advances in Experimental Medicine and Biology; vol. 1366). Available at: https:\/\/link.springer.com\/10.1007\/978-981-16-8702-0_1","DOI":"10.1007\/978-981-16-8702-0_1"},{"key":"1535_CR16","volume":"7","author":"L Sun","year":"2024","unstructured":"Sun L, Chen B, Liu X, Zhu Y, Zhang G, Liang X, et al. Alpaca-derived nanobody targeting the hydrophobic pocket of the HIV-1 gp41 NHR broadly neutralizes HIV-1 by blocking six-helix bundle formation. Curr Res Micro Sci. 2024;7:100263.","journal-title":"Curr Res Micro Sci"},{"key":"1535_CR17","doi-asserted-by":"publisher","first-page":"3659","DOI":"10.3390\/ijms25073659","volume":"25","author":"B Sever","year":"2024","unstructured":"Sever B, Otsuka M, Fujita M, Ciftci H. A review of FDA-approved anti-HIV-1 drugs, anti-gag compounds, and potential strategies for HIV-1 eradication. Int J Mol Sci. 2024;25:3659.","journal-title":"Int J Mol Sci"},{"key":"1535_CR18","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1038\/s41589-020-0496-y","volume":"16","author":"T Xiao","year":"2020","unstructured":"Xiao T, Frey G, Fu Q, Lavine CL, Scott DA, Seaman MS. et al. HIV-1 fusion inhibitors targeting the membrane-proximal external region of Env spikes. Nat Chem Biol. 2020;16:529\u201337.","journal-title":"Nat Chem Biol"},{"key":"1535_CR19","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1038\/s41589-020-0521-1","volume":"16","author":"S Su","year":"2020","unstructured":"Su S, Jiang S. Anti-HIV agents inspired by antibodies. Nat Chem Biol. 2020;16:483\u20134.","journal-title":"Nat Chem Biol"},{"key":"1535_CR20","doi-asserted-by":"publisher","first-page":"1379","DOI":"10.1126\/science.abf4896","volume":"371","author":"RD de Vries","year":"2021","unstructured":"de Vries RD, Schmitz KS, Bovier FT, Predella C, Khao J, Noack D. et al. Intranasal fusion inhibitory lipopeptide prevents direct-contact SARS-CoV-2 transmission in ferrets. Science. 2021;371:1379\u201382.","journal-title":"Science"},{"key":"1535_CR21","volume":"6","author":"Q Lan","year":"2024","unstructured":"Lan Q, Yan Y, Zhang G, Xia S, Zhou J, Lu L, et al. Clinical development of antivirals against SARS-CoV-2 and its variants. Curr Res Micro Sci. 2024;6:100208.","journal-title":"Curr Res Micro Sci"},{"key":"1535_CR22","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1007\/978-981-16-8702-0_7","volume":"1366","author":"Q Lan","year":"2022","unstructured":"Lan Q, Xia S, Lu L. Coronavirus entry inhibitors. Adv Exp Med Biol. 2022;1366:101\u201321.","journal-title":"Adv Exp Med Biol"},{"key":"1535_CR23","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00831-17","volume":"91","author":"X Ding","year":"2017","unstructured":"Ding X, Zhang X, Chong H, Zhu Y, Wei H, Wu X. et al. Enfuvirtide (T20)-based lipopeptide is a potent HIV-1 cell fusion inhibitor: implications for viral entry and inhibition. J Virol. 2017;91:e00831-17","journal-title":"J Virol"},{"key":"1535_CR24","doi-asserted-by":"publisher","first-page":"735","DOI":"10.3390\/v13050735","volume":"13","author":"T Xiao","year":"2021","unstructured":"Xiao T, Cai Y, Chen B. HIV-1 entry and membrane fusion inhibitors. Viruses. 2021;13:735","journal-title":"Viruses"},{"key":"1535_CR25","doi-asserted-by":"publisher","first-page":"e1009103","DOI":"10.1371\/journal.ppat.1009103","volume":"16","author":"M Khamassi","year":"2020","unstructured":"Khamassi M, Xu L, Rey J, Duchemin M, Bouceba T, Tuffery P, et al. The CH1\u03b1 domain of mucosal gp41 IgA contributes to antibody specificity and antiviral functions in HIV-1 highly exposed Sero-Negative individuals. PLoS Pathog. 2020;16:e1009103.","journal-title":"PLoS Pathog"},{"key":"1535_CR26","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1016\/j.immuni.2011.01.015","volume":"34","author":"M Bomsel","year":"2011","unstructured":"Bomsel M, Tudor D, Drillet AS, Alfsen A, Ganor Y, Roger MG. et al. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity. 2011;34:269\u201380.","journal-title":"Immunity"},{"key":"1535_CR27","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1038\/nature11544","volume":"491","author":"J Huang","year":"2012","unstructured":"Huang J, Ofek G, Laub L, Louder MK, Doria-Rose NA, Longo NS, et al. Broad and potent neutralization of HIV-1 by a gp41-specific human antibody. Nature. 2012;491:406\u201312.","journal-title":"Nature"},{"key":"1535_CR28","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1089\/08892220152741450","volume":"17","author":"G Stiegler","year":"2001","unstructured":"Stiegler G, Kunert R, Purtscher M, Wolbank S, Voglauer R, Steindl F. et al. A potent cross-clade neutralizing human monoclonal antibody against a novel epitope on gp41 of human immunodeficiency virus type 1. AIDS Res Hum Retroviruses. 2001;17:1757\u201365.","journal-title":"AIDS Res Hum Retroviruses"},{"key":"1535_CR29","doi-asserted-by":"publisher","first-page":"12680","DOI":"10.1073\/pnas.1200024109","volume":"109","author":"D Tudor","year":"2012","unstructured":"Tudor D, Yu H, Maupetit J, Drillet AS, Bouceba T, Schwartz-Cornil I. et al. Isotype modulates epitope specificity, affinity, and antiviral activities of anti-HIV-1 human broadly neutralizing 2F5 antibody. Proc Natl Acad Sci USA. 2012;109:12680\u20135.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1535_CR30","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1128\/JVI.72.2.986-993.1998","volume":"72","author":"LT Rimsky","year":"1998","unstructured":"Rimsky LT, Shugars DC, Matthews TJ. Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol. 1998;72:986\u201393.","journal-title":"J Virol"},{"key":"1535_CR31","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1038\/mi.2009.89","volume":"2","author":"D Tudor","year":"2009","unstructured":"Tudor D, Derrien M, Diomede L, Drillet AS, Houimel M, Moog C, et al. HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4+ cell infection: an IgA gene and functional analysis. Mucosal Immunol. 2009;2:412\u201326.","journal-title":"Mucosal Immunol"},{"key":"1535_CR32","doi-asserted-by":"publisher","first-page":"3739","DOI":"10.1073\/pnas.0800255105","volume":"105","author":"G Frey","year":"2008","unstructured":"Frey G, Peng H, Rits-Volloch S, Morelli M, Cheng Y, Chen B. A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies. Proc Natl Acad Sci USA. 2008;105:3739\u201344.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1535_CR33","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1097\/00042560-199610010-00002","volume":"13","author":"T Keler","year":"1996","unstructured":"Keler T, Li H, Cloyd MW, Vitale LA, Deo YM. Development of T-cell lines expressing functional HIV-1 envelope glycoproteins for evaluation of immune responses in HIV-infected individuals. J Acquir Immune Defic Syndr Hum Retrovirol. 1996;13:117\u201326.","journal-title":"J Acquir Immune Defic Syndr Hum Retrovirol."},{"key":"1535_CR34","doi-asserted-by":"publisher","first-page":"10213","DOI":"10.1128\/JVI.72.12.10213-10217.1998","volume":"72","author":"S Jiang","year":"1998","unstructured":"Jiang S, Lin K, Lu M. A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the human immunodeficiency virus type 1 envelope glycoprotein. J Virol. 1998;72:10213\u20137.","journal-title":"J Virol"},{"key":"1535_CR35","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1128\/JVI.01594-12","volume":"87","author":"A Duverger","year":"2013","unstructured":"Duverger A, Wolschendorf F, Zhang M, Wagner F, Hatcher B, Jones J. et al. An AP-1 binding site in the enhancer\/core element of the HIV-1 promoter controls the ability of HIV-1 to establish latent infection. J Virol. 2013;87:2264\u201377.","journal-title":"J Virol"},{"key":"1535_CR36","doi-asserted-by":"publisher","first-page":"1545","DOI":"10.1097\/QAD.0000000000002208","volume":"33","author":"W Xu","year":"2019","unstructured":"Xu W, Pu J, Su S, Hua C, Su X, Wang Q, et al. Revisiting the mechanism of enfuvirtide and designing an analog with improved fusion inhibitory activity by targeting triple sites in gp41. AIDS. 2019;33:1545.","journal-title":"AIDS"},{"key":"1535_CR37","doi-asserted-by":"publisher","first-page":"8793","DOI":"10.1128\/JVI.00598-07","volume":"81","author":"A Manrique","year":"2007","unstructured":"Manrique A, Rusert P, Joos B, Fischer M, Kuster H, Leemann C. et al. In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10. J Virol. 2007;81:8793\u2013808.","journal-title":"J Virol"},{"key":"1535_CR38","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jim.2013.11.022","volume":"0","author":"M Sarzotti-Kelsoe","year":"2014","unstructured":"Sarzotti-Kelsoe M, Bailer RT, Turk E, Lin Cli, Bilska M, Greene KM. et al. Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J Immunol Methods. 2014;0:131\u201346.","journal-title":"J Immunol Methods"},{"key":"1535_CR39","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1128\/JVI.01629-06","volume":"81","author":"M Sourisseau","year":"2007","unstructured":"Sourisseau M, Sol-Foulon N, Porrot F, Blanchet F, Schwartz O. Inefficient human immunodeficiency virus replication in mobile lymphocytes. J Virol. 2007;81:1000\u201312.","journal-title":"J Virol"},{"key":"1535_CR40","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1016\/j.it.2014.08.007","volume":"35","author":"H Mouquet","year":"2014","unstructured":"Mouquet H. Antibody B cell responses in HIV-1 infection. Trends Immunol. 2014;35:549\u201361.","journal-title":"Trends Immunol"},{"key":"1535_CR41","doi-asserted-by":"publisher","first-page":"11126","DOI":"10.1074\/jbc.M800200200","volume":"283","author":"Y He","year":"2008","unstructured":"He Y, Xiao Y, Song H, Liang Q, Ju D, Chen X, et al. Design and evaluation of sifuvirtide, a novel HIV-1 fusion inhibitor. J Biol Chem. 2008;283:11126\u201334.","journal-title":"J Biol Chem"},{"key":"1535_CR42","doi-asserted-by":"publisher","first-page":"3924","DOI":"10.1128\/JVI.06478-11","volume":"86","author":"B Monel","year":"2012","unstructured":"Monel B, Beaumont E, Vendrame D, Schwartz O, Brand D, Mammano F. HIV cell-to-cell transmission requires the production of infectious virus particles and does not proceed through env-mediated fusion pores. J Virol. 2012;86:3924\u201333.","journal-title":"J Virol"},{"key":"1535_CR43","doi-asserted-by":"publisher","first-page":"e1002634","DOI":"10.1371\/journal.ppat.1002634","volume":"8","author":"IA Abela","year":"2012","unstructured":"Abela IA, Berlinger L, Schanz M, Reynell L, G\u00fcnthard HF, Rusert P, et al. Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies. PLoS Pathog. 2012;8:e1002634.","journal-title":"PLoS Pathog"},{"key":"1535_CR44","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1126\/science.3646751","volume":"236","author":"Y Koyanagi","year":"1987","unstructured":"Koyanagi Y, Miles S, Mitsuyasu RT, Merrill JE, Vinters HV, Chen ISY. Dual infection of the central nervous system by AIDS viruses with distinct cellular tropisms. Science. 1987;236:819\u201322.","journal-title":"Science"},{"key":"1535_CR45","doi-asserted-by":"publisher","first-page":"5801","DOI":"10.1073\/pnas.0901007106","volume":"106","author":"P Ingallinella","year":"2009","unstructured":"Ingallinella P, Bianchi E, Ladwa NA, Wang YJ, Hrin R, Veneziano M. et al. Addition of a cholesterol group to an HIV-1 peptide fusion inhibitor dramatically increases its antiviral potency. Proc Natl Acad Sci USA. 2009;106:5801\u20136.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1535_CR46","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abn1413","volume":"14","author":"BL Hartwell","year":"2022","unstructured":"Hartwell BL, Melo MB, Xiao P, Lemnios AA, Li N, Chang JYH. et al. Intranasal vaccination with lipid-conjugated immunogens promotes antigen transmucosal uptake to drive mucosal and systemic immunity. Sci Transl Med. 2022;14:eabn1413.","journal-title":"Sci Transl Med"},{"key":"1535_CR47","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.antiviral.2011.04.002","volume":"92","author":"B Berkhout","year":"2011","unstructured":"Berkhout B, Sanders RW. Molecular strategies to design an escape-proof antiviral therapy. Antivir Res. 2011;92:7\u201314.","journal-title":"Antivir Res"},{"key":"1535_CR48","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/nature09385","volume":"467","author":"H Mouquet","year":"2010","unstructured":"Mouquet H, Scheid JF, Zoller MJ, Krogsgaard M, Ott RG, Shukair S. et al. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature. 2010;467:591\u20135.","journal-title":"Nature"},{"key":"1535_CR49","doi-asserted-by":"publisher","first-page":"7552","DOI":"10.1073\/pnas.0802203105","volume":"105","author":"BF Keele","year":"2008","unstructured":"Keele BF, Giorgi EE, Salazar-Gonzalez JF, Decker JM, Pham KT, Salazar MG. et al. Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc Natl Acad Sci USA. 2008;105:7552\u20137.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1535_CR50","doi-asserted-by":"crossref","unstructured":"Nijmeijer BM, Geijtenbeek TBH. Negative and positive selection pressure during sexual transmission of transmitted founder HIV-1. Front Immunol. 2019;10. Available at: https:\/\/www.frontiersin.org\/journals\/immunology\/articles\/10.3389\/fimmu.2019.01599\/full","DOI":"10.3389\/fimmu.2019.01599"},{"key":"1535_CR51","doi-asserted-by":"crossref","unstructured":"Wu X, Parast AB, Richardson BA, Nduati R, John-Stewart G, Mbori-Ngacha D, et al. Neutralization escape variants of human immunodeficiency virus type 1 are transmitted from mother to infant. J Virol. 2006;80. Available at: https:\/\/pubmed.ncbi.nlm.nih.gov\/16378985\/","DOI":"10.1128\/JVI.80.2.835-844.2006"},{"key":"1535_CR52","doi-asserted-by":"publisher","first-page":"6626","DOI":"10.1073\/pnas.1304288110","volume":"110","author":"NF Parrish","year":"2013","unstructured":"Parrish NF, Gao F, Li H, Giorgi EE, Barbian HJ, Parrish EH. et al. Phenotypic properties of transmitted founder HIV-1. Proc Natl Acad Sci USA. 2013;110:6626\u201333.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1535_CR53","doi-asserted-by":"publisher","first-page":"1254031","DOI":"10.1126\/science.1254031","volume":"345","author":"JM Carlson","year":"2014","unstructured":"Carlson JM, Schaefer M, Monaco DC, Batorsky R, Claiborne DT, Prince J. et al. Selection bias at the heterosexual HIV-1 transmission bottleneck. Science. 2014;345:1254031.","journal-title":"Science"},{"key":"1535_CR54","doi-asserted-by":"publisher","first-page":"E590","DOI":"10.1073\/pnas.1620144114","volume":"114","author":"SS Iyer","year":"2017","unstructured":"Iyer SS, Bibollet-Ruche F, Sherrill-Mix S, Learn GH, Plenderleith L, Smith AG. et al. Resistance to type 1 interferons is a major determinant of HIV-1 transmission fitness. Proc Natl Acad Sci USA. 2017;114:E590\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1535_CR55","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1002\/jps.20150","volume":"93","author":"B Ashok","year":"2004","unstructured":"Ashok B, Arleth L, Hjelm RP, Rubinstein I, \u00d6ny\u00fcksel H. In vitro characterization of PEGylated phospholipid micelles for improved drug solubilization: effects of PEG chain length and PC incorporation. J Pharm Sci. 2004;93:2476\u201387.","journal-title":"J Pharm Sci"},{"key":"1535_CR56","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1016\/j.addr.2003.12.004","volume":"56","author":"AN Lukyanov","year":"2004","unstructured":"Lukyanov AN, Torchilin VP. Micelles from lipid derivatives of water-soluble polymers as delivery systems for poorly soluble drugs. Adv Drug Deliv Rev. 2004;56:1273\u201389.","journal-title":"Adv Drug Deliv Rev"},{"key":"1535_CR57","doi-asserted-by":"publisher","DOI":"10.1038\/srep31750","volume":"6","author":"A Brown","year":"2016","unstructured":"Brown A, Patel S, Ward C, Lorenz A, Ortiz M, DuRoss A. et al. PEG-lipid micelles enable cholesterol efflux in Niemann-Pick Type C1 disease-based lysosomal storage disorder. Sci Rep. 2016;6:31750.","journal-title":"Sci Rep"},{"key":"1535_CR58","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1038\/nature04817","volume":"441","author":"P Zhu","year":"2006","unstructured":"Zhu P, Liu J, Bess J, Chertova E, Lifson JD, Gris\u00e9 H. et al. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature. 2006;441:847\u201352.","journal-title":"Nature"},{"key":"1535_CR59","doi-asserted-by":"crossref","unstructured":"Stano A, Leaman DP, Kim AS, Zhang L, Autin L, Ingale J, et al. Dense array of spikes on HIV-1 virion particles. J Virol. 2017;91. Available at: https:\/\/www.ncbi.nlm.nih.gov\/pmc\/articles\/PMC5487557\/","DOI":"10.1128\/JVI.00415-17"},{"key":"1535_CR60","doi-asserted-by":"publisher","first-page":"5323","DOI":"10.1074\/jbc.RA118.001729","volume":"293","author":"Y Zhu","year":"2018","unstructured":"Zhu Y, Zhang X, Ding X, Chong H, Cui S, He J. et al. Exceptional potency and structural basis of a T1249-derived lipopeptide fusion inhibitor against HIV-1, HIV-2, and simian immunodeficiency virus. J Biol Chem. 2018;293:5323\u201334.","journal-title":"J Biol Chem"}],"container-title":["Acta Pharmacologica Sinica"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01535-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01535-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01535-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T08:03:01Z","timestamp":1761292981000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41401-025-01535-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,5]]},"references-count":60,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["1535"],"URL":"https:\/\/doi.org\/10.1038\/s41401-025-01535-5","relation":{},"ISSN":["1671-4083","1745-7254"],"issn-type":[{"value":"1671-4083","type":"print"},{"value":"1745-7254","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,5]]},"assertion":[{"value":"8 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}